Pharmaceuticals company Cipla announced Q4FY26 & FY26 results Consolidated Financial Highlights: Quarterly Revenue: Revenue from operations for Q4FY26 stood at Rs 6,541.20 crore, representing a decrease of 2.80% YoY compared to Rs 6,729.69 crore in Q4FY25. On a QoQ basis, revenue declined 7.54% from Rs 7,074.48 crore in Q3FY26. Quarterly EBITDA: Consolidated EBITDA for Q4FY26 was Rs 997 crore, with an EBITDA margin of 15.2% of income from operations. Quarterly Profit After Tax (PAT): PAT attributable to owners of the parent for Q4FY26 was Rs 554.64 crore, a decrease of 54.61% YoY from Rs 1,221.84 crore and a decline of 17.93% QoQ from Rs 675.80 crore. Annual Revenue: For the full year FY26, consolidated revenue from operations reached Rs 28,162.59 crore, marking a growth of 2.23% YoY compared to Rs 27,547.62 crore in FY25. Annual EBITDA: EBITDA for FY26 stood at Rs 5,925 crore, with a margin of 21.0%. Annual Profit After Tax (PAT): Annual PAT attributable to owners for FY26 was Rs 3,879.23 crore, a decrease of 26.43% YoY compared to Rs 5,272.52 crore in FY25. Cash Position: The company reported a strong net cash position of Rs 10,526 crore as of March 31, 2026. Standalone Financial Highlights: Quarterly Revenue: Standalone revenue from operations for Q4FY26 was Rs 4,209.98 crore, a decline of 12.25% YoY from Rs 4,797.89 crore and a decrease of 6.40% QoQ from Rs 4,498.08 crore. Quarterly Profit After Tax (PAT): Standalone PAT for Q4FY26 was Rs 384.64 crore, down 74.11% YoY from Rs 1,485.40 crore and 37.65% QoQ from Rs 616.88 crore. Annual Revenue: For the full year FY26, standalone revenue was Rs 18,979.95 crore, a marginal decrease of 0.34% YoY from Rs 19,044.85 crore in FY25. Annual Profit After Tax (PAT): Standalone annual PAT stood at Rs 3,515.18 crore, a decline of 31.85% YoY from Rs 5,157.65 crore in FY25. Dividend: The Board of Directors has recommended a final dividend of Rs 13 per equity share (face value of Rs 2 each) for the financial year ended March 31, 2026. Business Highlights: One India Business: This segment surpassed the Rs 12,500 crore annual revenue milestone in FY26. Quarterly sales for Q4FY26 grew by 15% YoY to Rs 3,007 crore. Branded Prescription: Sustained growth in key chronic therapies (Respiratory, Urology, Anti-diabetes, and Cardiac). The chronic mix stood at 60.2%. The brand Foracort surpassed the Rs 1,000 crore threshold. Trade Generics: Maintained strong double-digit growth supported by execution excellence and new introductions. Consumer Health (CHL): Anchor brands like Nicotex, Omnigel, and Cipladine maintained leadership positions in their respective market segments. North America: Delivered Q4FY26 revenue of USD 155 million and annual revenue of USD 780 million. The business secured regulatory approval for the first AB-rated gVentolin, the first commercial MDI product to be manufactured from the company's U.S. facility. One Africa: Achieved robust quarterly growth of 21% YoY to Rs 1,236 crore. In South Africa specifically, quarterly revenue grew 33% YoY to Rs 984 crore. Emerging Markets and Europe: The segment surpassed the USD 400 million annual revenue milestone. Q4FY26 sales stood at Rs 819 crore. R&D; Investments: For Q4FY26, R&D; investment was Rs 509 crore, or 7.8% of sales, driven by product filings and development efforts. Regulatory Update: USFDA completed inspections at manufacturing facilities in Bommasandra (Bengaluru), Sitec (Navi Mumbai), and Medispray (Goa), with all receiving 'VAI' or 'NAI' classifications. Achin Gupta, MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In FY26, we recorded our highest-ever yearly revenue of Rs. 28,163 crore, reflecting the strength of our core businesses despite certain markets facing near-term challenges. Our One-India business surpassed the Rs. 12,500 crore annual revenue milestone. Key therapies in Branded Prescription business delivered robust double-digit growth, Trade Generics business sustained the strong growth momentum and anchor brands of Consumer Health Business maintained leadership position. The US business posted an annual revenue of USD 780 million supported by demand in our differentiated portfolio and a steady base business. In One Africa, we recorded a healthy annual growth of 7% YoY in USD terms, driven by firm performance across key markets. Emerging Markets and Europe crossed the USD 400 million+ annualised revenue threshold on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”. Result PDF